Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. (HKG:1349)
Hong Kong · Delayed Price · Currency is HKD 2.820
+0.030 (1.06%)
Apr 21, 2026, 4:08 PM HKT
HKG:1349 Revenue
In the year 2025, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical had annual revenue of 685.80M CNY, down -3.33%. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical had revenue of 134.72M in the quarter ending December 31, 2025, a decrease of -16.09%.
Revenue
685.80M CNY
Revenue Growth
-3.33%
P/S Ratio
9.50
Revenue / Employee
762.84K CNY
Employees
899
Market Cap
7.25B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 685.80M | -23.61M | -3.33% |
| Dec 31, 2024 | 709.40M | -141.33M | -16.61% |
| Dec 31, 2023 | 850.73M | -180.43M | -17.50% |
| Dec 31, 2022 | 1.03B | -109.15M | -9.57% |
| Dec 31, 2021 | 1.14B | 306.51M | 36.76% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| China Traditional Chinese Medicine Holdings Co. | 16.41B |
| Shandong Xinhua Pharmaceutical Company | 9.74B |
| Luye Pharma Group | 7.02B |
| SSY Group | 4.17B |
| Consun Pharmaceutical Group | 3.80B |
| China Shineway Pharmaceutical Group | 3.49B |
| Sihuan Pharmaceutical Holdings Group | 2.91B |
| Edding Genor Group Holdings | 2.77B |